Cologne, North Rhine-Westphalia, Germany
I currently serve as Chief Operating Officer and Head of Computational Biology at DISCO Pharmaceuticals. I have more than a decade of senior management experience with a successful track record in company building as well as leading Research & Development and operational activities in the biotech and diagnostics industry. Before co-founding DISCO, I co-founded PearlRiver Bio (acquired by Centessa in 2021) and led the discovery of its next generation EGFR inhibitors as CSO. Earlier, as co-founder and CSO of NEO New Oncology (acquired by Siemens in 2016) I developed CE-IVD-labeled next-generation sequencing (NGS) diagnostic tests and successfully built a start-up into a company with more than 50 employees.